Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-30

Study Completion Date

2027-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IMPAACT 2044 is a study to characterize the pharmacokinetics (PK) and safety of ceftriaxone and benzathine penicillin G during pregnancy. Up to 78 pregnant women receiving (1) ceftriaxone for indications other than syphilis or (2) benzathine penicillin G for treatment of syphilis from non-study clinical care providers will be enrolled at study sites located in the United States. Approximately 22 infants of pregnant participants receiving benzathine penicillin G will also be enrolled.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Antimicrobial Prophylaxis to Prevent Syphilis in Pregnancy in Patients at Risk in Rio de Janeiro, Brazil

NCT07189208

Congenital Syphilis

RECRUITING PHASE2

Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy

NCT05309928

Pregnancy Related

COMPLETED PHASE1

A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

NCT00532324

Staphylococcus Aureus

COMPLETED NA

Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.

NCT01540227

Syphilis Primary Syphilis Secondary Syphilis +1 more

TERMINATED

Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis

NCT06527560

Pyelonephritis in Pregnancy

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IMPAACT 2044 is a Phase IV, multi-site, open-label, non-randomized, opportunistic study to characterize the pharmacokinetics (PK) and safety of ceftriaxone and benzathine penicillin G during pregnancy.

The study includes two arms, with Arm 1 subdivided by route of administration:

Arm 1A: Intravenous (IV) ceftriaxone Arm 1B: Intramuscular (IM) ceftriaxone Arm 2: IM benzathine penicillin G

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active comparator: Arm 1A: IV ceftriaxone

Intravenous ceftriaxone

Ceftriaxon

Intervention Type DRUG

Ceftriaxone will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider

Active Comparator: Arm 1B: IM ceftriaxone

Intramuscular ceftriaxone

Ceftriaxon

Intervention Type DRUG

Ceftriaxone will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider

Active Comparator: Arm 2: IM benzathine penicillin G

Intramuscular benzathine penicillin G

Benzathine penicillin G

Intervention Type DRUG

Benzathine penicillin G will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ceftriaxon

Ceftriaxone will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider

Intervention Type DRUG

Benzathine penicillin G

Benzathine penicillin G will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is of legal age or circumstance to provide independent informed consent as determined by site standard operating procedures (SOPs) and consistent with Institutional Review Board (IRB) policies and procedures and is willing and able to provide written informed consent for her own and, if applicable (Arm 2), her infant's study participation
* At screening, has a viable singleton intrauterine pregnancy of any gestational age confirmed by fetal ultrasound, as determined by the site investigator based on medical records, with trimester documented based on the best available obstetric estimate
* At screening, is receiving or expected to receive one of the following drugs under study as prescribed by a clinical care provider and documented in medical records:

* Ceftriaxone: IV or IM administration for an indication other than syphilis
* Benzathine penicillin G: IM administration for treatment of syphilis
* At entry, expects to remain in the geographic area of the study site during pregnancy and at least 30 days postpartum

Exclusion Criteria

* Previously enrolled in this study
* Requires desensitization to ceftriaxone or benzathine penicillin G as determined by the site investigator based on pregnant participant report and available medical records
* Has any of the following as determined by the site investigator based on pregnant participant report and available medical records:

* Current indication for hemodialysis
* Current indication for intensive care unit hospitalization
* Creatinine (Cr) ≥ 3.5 x upper limit of normal (ULN) at any time during the current pregnancy and/or chronic kidney disease Stage 5
* Receipt of any of the following prohibited medications within seven days prior to entry as determined by the site investigator based on pregnant participant report and available medical records:

* Probenecid
* Penicillin
* Arm 1A: any penicillin
* Arm 1B: any penicillin
* Arm 2: penicillin other than benzathine penicillin G

* Benzapril
* Chlorpropamide
* Diflunisal
* Irbesartan
* Ketoprofen
* Ketorolac tromethamine
* Meclofenamic acid
* Mefenamic acid
* Oxaprozin
* Parecoxib
* Penciclovir
* Pioglitazone
* Telmisartan
* Valsartan
* Receipt of any investigational agent within seven days prior to entry as determined by the site investigator based on pregnant participant report and available medical records
* Has any documented or suspected clinically significant condition that, in the opinion of the site investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No